COMMUNIQUÉS West-GlobeNewswire
-
BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026
15/04/2026 -
Ardena Opens New Bioanalytical Laboratory in Somerset, New Jersey
15/04/2026 -
60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website
15/04/2026 -
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
15/04/2026 -
Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data
15/04/2026 -
Reviva Announces Letter to Shareholders
15/04/2026 -
Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions
15/04/2026 -
Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
15/04/2026 -
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
15/04/2026 -
Callio Therapeutics to Present Poster on CLIO-8221, a Novel Dual-Payload Antibody-Drug Conjugate, at AACR 2026
15/04/2026 -
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
15/04/2026 -
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
15/04/2026 -
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
15/04/2026 -
BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy
15/04/2026 -
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
15/04/2026 -
TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI
15/04/2026 -
Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
15/04/2026 -
Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression
15/04/2026 -
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
15/04/2026
Pages